🇺🇸·7h agoIndustry
Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
Publisher
A
AbbVie News
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- AbbVie News
- Region
- USA
- Scope
- Industry
- Published
- June 23, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on news.abbvie.com
Leave the platform to read the original full article on the publisher site.
Source: AbbVie News
Scope: Industry
Related coverage
More related coverage
Certara/2h ago
Certara Launches Bio Venture Catalyst for Emerging Biotechs to De-risk Investment and Accelerate Development
Certara/3h ago
Integrating Endogenous Ligand Competition into a Mechanistic Whole-Body PBPK Model of Therapeutic Monoclonal Antibodies
CSafe Global/3h ago
ULD Container vs.Non-ULD Container: What Is the Difference?
Certara/3h ago